Investigation of the Effects of Noncoding LDLR Variants on Hyperlipidaemia risk
Human Heredity · 10.07.2026 · 91 (1) · 46-51
DOI: 10.1159/000553528 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Heredity, online erschienen am 10.07.2026. Verfasst von Daniela Rojano und 1 weiteren Autor:innen. Beteiligte Einrichtung: UCL Genetics Institute, University College London, London, UK. Hauptthemen laut MEDLINE: Receptors, LDL, Hyperlipidemias, Genetic Predisposition to Disease. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Coding and noncoding variants of the LDLR gene have been reported to cause familial hyperlipidaemia (FH) and rare coding variants have been shown to increase risk of hyperlipidaemia in the general population.
Methods
Hyperlipidaemia status had previously been assigned for 470,000 UK Biobank participants in a study of rare coding variants. Effects of variants obtained from whole-genome sequencing in the five-prime untranslated region (5′UTR) and promoter region of LDLR were analysed using this phenotype. Variants previously reported to be implicated in FH and associated with altered LDLR expression were entered into logistic regression analysis. Other variants in these regions with minor allele frequency ≤0.01 were entered into a weighted burden test. For this analysis, insertion-deletion variants were weighted according to rarity while single-nucleotide variants were additionally weighted using 2 pathogenicity predictors, CADD and GPN-MSA.
Results
The previously reported common variant, rs17248720C>T, was confirmed to slightly reduce hyperlipidaemia risk. Two previously reported rare variants which were associated with markedly reduced LDLR expression, c.-101T>C and c.-121T>C, had at most only moderate effects on hyperlipidaemia risk. In the weighted burden analysis, promoter variants annotated with CADD showed evidence for association with increased risk (p = 0.00097). However, the effect size was small, with variants having CADD scores exceeding 0.5 having OR = 1.07 (0.99–1.15).
Conclusion
Although rare noncoding variants do have detectable effects on hyperlipidaemia risk, these effects are much smaller than those detected for coding variants in the same sample. This research has been conducted using the UK Biobank Resource.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Genetics Institute, University College London, London, UK.
- UCL Genetics Institute, University College London, London, UK, d.curtis@ucl.ac.uk.
Zitieren
APA
Rojano, D., & Curtis, D. (2026). Investigation of the Effects of Noncoding LDLR Variants on Hyperlipidaemia risk. Human Heredity, 91(1), 46-51. https://doi.org/10.1159/000553528
Vancouver
Rojano D, Curtis D. Investigation of the Effects of Noncoding LDLR Variants on Hyperlipidaemia risk. Human Heredity. 2026;91(1):46-51. doi:10.1159/000553528
BibTeX
@article{Rojano2026,
author = {Rojano, Daniela and Curtis, David},
title = {Investigation of the Effects of Noncoding LDLR Variants on Hyperlipidaemia risk},
journal = {Human Heredity},
year = {2026},
volume = {91},
number = {1},
pages = {46--51},
doi = {10.1159/000553528}
}
EUVIMED